MedTrace Logo

Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer

NCT02107391 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2017-05-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether DCVAC/PCa added onto hormone therapy can improve PSA progression times for patients with Metastatic Prostate Cancer.

Conditions

Interventions

BIOLOGICAL

Dendritic Cells DCVAC/PCa

Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy

DRUG

Leuprolide acetate

Standard of Care Hormone Therapy as an Active Comparator

DRUG

Goserelin Acetate

Standard of Care Hormone Therapy as an Active Comparator

Sponsors & Collaborators

  • SOTIO a.s.

    lead INDUSTRY

Principal Investigators

  • Tomas Scheiner, PhD · Sotio-Accord

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2015-12-31
Completion
2016-06-30

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02107391 on ClinicalTrials.gov